Developing Biomarker Combinations in Multicenter Studies via Direct
  Maximization and Penalization by Meisner, Allison et al.
Developing Biomarker Combinations in Multicenter
Studies via Direct Maximization and Penalization
Allison Meisner
Department of Biostatistics, Johns Hopkins University, Baltimore, MD, USA
Corresponding author: ameisne1@jhu.edu
Chirag R. Parikh
Division of Nephrology, Johns Hopkins University, Baltimore, MD, USA
Kathleen F. Kerr
Department of Biostatistics, University of Washington, Seattle, WA, USA
Abstract
Motivated by a study of acute kidney injury, we consider the setting of biomarker stud-
ies involving patients at multiple centers where the goal is to develop a biomarker combina-
tion for diagnosis, prognosis, or screening. As biomarker studies become larger, this type
of data structure will be encountered more frequently. In the presence of multiple centers,
one way to assess the predictive capacity of a given combination is to consider the center-
adjusted AUC (aAUC), a summary of the ability of the combination to discriminate between
cases and controls in each center. Rather than using a general method, such as logistic re-
gression, to construct the biomarker combination, we propose directly maximizing the aAUC.
Furthermore, it may be desirable to have a biomarker combination with similar performance
across centers. To that end, we allow for penalization of the variability in the center-specific
AUCs. We demonstrate desirable asymptotic properties of the resulting combinations. Sim-
ulations provide small-sample evidence that maximizing the aAUC can lead to combinations
with improved performance. We also use simulated data to illustrate the utility of constructing
combinations by maximizing the aAUC while penalizing variability. Finally, we apply these
methods to data from the study of acute kidney injury.
Keywords: Adjusted AUC; Biomarker combinations; Multicenter; Penalization.
Short title: Biomarker combinations via maximization and penalization
1 Introduction
Multicenter studies have long been used in therapeutic settings as a way to increase power and
improve generalizability and are increasingly common in biomarker studies (e.g.,1–3). In addition,
it is now feasible to measure many biomarkers on each participant. As the performance of indi-
vidual biomarkers is often modest, there is interest in developing combinations of biomarkers for
prognosis, diagnosis, and screening. When studies of multiple biomarkers also involve multiple
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centers, the central question becomes how such biomarker combinations should be constructed. In
a given multicenter study, only a sample of centers are observed. Without making strong distri-
butional assumptions, it is not possible to provide predicted probabilities for individuals in a new
center. Acknowledging this inherent limitation of the study design, we aim to identify promising
biomarker combinations for further development.
The Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-
AKI) study is an example of a multicenter biomarker study. The TRIBE-AKI study collected data
from 1219 cardiac surgery patients at six centers in North America4. Study participants were
followed for diagnosis of acute kidney injury (AKI) during hospitalization; in other words, the
participants were hospitalized in order to undergo cardiac surgery and were followed postopera-
tively for signs of AKI. For each patient, blood and urine were collected at multiple time points pre-
and postoperatively, and several biomarkers were measured at each time point. AKI is typically
diagnosed via changes in serum creatinine, but these changes often do not happen until several
days after the injury occurs. The goal of the study was to identify a combination of biomarkers
that can provide an earlier diagnosis of AKI.
Methods to construct biomarker combinations by maximizing the area under the receiver op-
erating characteristic (ROC) curve (AUC) have been proposed. However, in the multicenter set-
ting, there is interest in conditional performance. One measure of conditional performance is the
center-adjusted AUC (aAUC). We propose a method to construct linear biomarker combinations
by targeting the aAUC. We then extend our method to allow for penalization of the variability in
center-specific performance, yielding combinations with good overall performance and more simi-
lar performance across centers. We provide theoretical and empirical justification for the proposed
methods and apply these methods to data from the TRIBE-AKI study.
2 Background
Let D be a binary outcome, where cases are denoted by D = 1 or the subscript D and controls are
denoted by D = 0 or the subscript D¯.
2.1 Center-adjusted AUC
Without loss of generality, suppose that for a given predictor Z, higher values of Z are more indica-
tive of D= 1. Thus, for a particular threshold δ , the true and false positive rates are P(Z > δ |D= 1)
and P(Z > δ |D= 0), respectively. The ROC curve for Z plots the true positive rate versus the false
positive rate over the range of possible thresholds δ 5. The area under the ROC curve (AUC) is a
measure of the ability of Z to discriminate between cases and controls, one aspect of the predictive
capacity of Z. The ROC curve for a useless predictor lies on the 45-degree line, and the corre-
sponding AUC is 0.55. The ROC curve for a perfect predictor reaches the upper left-hand corner
of the unit square, and its AUC is 15. The AUC can also be interpreted as the probability that Z for
a randomly chosen case is larger than Z for a randomly chosen control5.
In the multicenter setting, Z can be evaluated marginally, by considering the AUC for Z pooled
across centers, or conditionally, by summarizing center-specific AUCs. If a measure of marginal
performance (i.e., the AUC for Z pooled across centers) is used, center is allowed to potentially
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influence the assessment of the discriminatory ability of Z, restricting interpretability and gener-
alizability6. Instead, performance should be assessed within each center and then summarized
across centers; this is analogous to the center-adjusted odds ratio in the etiologic setting and the
center-adjusted treatment effect in the therapeutic setting6,7. One such summary measure is the
center-adjusted AUC (aAUC).
The center-adjusted ROC (aROCZ) and corresponding center-adjusted AUC (aAUCZ) of Z,
proposed by8, can be written as
aAUCZ =
∫ 1
0
aROCZ(t)dt =
∫ 1
0
∑
c
ROCZ|C=c(t)P(C = c|D = 1)dt =∑
c
wcAUCZ|C=c,
where C indicates center, t denotes the false positive rate, ROCZ|C=c and AUCZ|C=c denote the
center-specific ROC and AUC, respectively, in center c, and wc = P(C = c|D= 1) is the proportion
of cases in center c. The aAUC is a weighted average of the center-specific AUCs9. Thus, it is
a summary of the ability of Z to discriminate between cases and controls in each center6. When
a sample of centers is used to estimate the aAUC of Z, the estimate provides insight into the
performance of Z in new centers, to the extent that the new centers are similar to those used to
estimate the aAUC. This is analogous to applying an estimate of a center-adjusted treatment effect
from a multicenter randomized trial to a new center.
2.2 Biomarker combinations
For a collection of biomarkers X, the combination P(D = 1|X) (and monotone increasing func-
tions thereof) is optimal in terms of maximizing the true positive rate at each false positive rate10.
Thus, to the extent that the linear logistic model holds, that is, P(D = 1|X) = expit(θ>X) for
some coefficient vector θ , the combination θ>X is optimal. As the linear logistic model may not
hold, methods have been developed to construct biomarker combinations by maximizing the AUC
without relying on this model11.
Methods have also been developed to identify combinations of biomarkers that maximize the
AUC while accommodating covariates12,13. However, implementation of the method proposed
by12 is computationally challenging or prohibitive for more than two biomarkers. The method
proposed by13 assumes that the biomarkers have multivariate normal distributions and requires
specification of the relationship between the covariates (e.g., center) and the biomarkers. Conse-
quently, these methods may not be broadly applicable.
If the same data are used to construct a biomarker combination and evaluate its performance
(by estimating the aAUC, for example), the resulting estimate of performance is optimistically
biased14. This bias, which we refer to as “resubstitution bias”15, can be addressed by using a
bootstrapping procedure to estimate the bias and correct the apparent estimate of performance14,16.
Bootstrapping assumes the observations are exchangeable, but in a multicenter study, observations
from the same center may be more similar than observations from different centers, leading to
clustering of the data by center; thus, bootstrap resampling by center has been suggested9,17–19.
However, similar results for the center-specific AUC have been found whether resampling was
done on centers or individual observations17.
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2.3 Smooth AUC approximations
When logistic regression is used to construct a combination, the fitted combination is obtained by
maximizing the logistic likelihood. However, we are interested in using combinations for diagno-
sis, prognosis, or screening. This motivates maximizing measures of performance, e.g., the AUC,
to construct a combination. Such direct maximization is compelling as it matches the objective
function to the intended use of the combination11,20. One benefit of directly maximizing the AUC
is that the resulting combination is optimal, in terms of the AUC, within the class of combina-
tions considered11. Furthermore, the AUC of a linear combination constructed by targeting the
AUC will be at least as large as the AUC for the individual biomarkers20. This simple, desirable
property might not hold when a combination is constructed by maximizing a likelihood.
In practice, for a set of biomarkersX, the true AUC for the linear combination θ>X is unknown.
Instead, we can consider the empirical AUC,
ˆAUC(θ) =
1
nDnD¯
nD
∑
i=1
nD¯
∑
j=1
1(θ>XDi > θ>XD¯ j),
where nD and nD¯ are the number of cases and controls, respectively, 1(·) is the indicator function,
XDi denotes the biomarker vector for the ith case, and XD¯ j denotes the biomarker vector for the
jth control. Since ˆAUC involves indicator functions, direct maximization is challenging. However,
smooth approximations to the empirical AUC have been proposed.21 used a smooth approximation
based on the the probit function:
ˆAUC(θ)≈ Rn(θ) = 1nDnD¯
nD
∑
i=1
nD¯
∑
j=1
Φ
{
θ>(XDi−XD¯ j)/h
}
,
where Φ is the standard normal distribution function and h is a tuning parameter. The function
Φ(v/h) serves as an approximation to the indicator function I(v > 0) and h represents the trade-off
between approximation accuracy and estimation feasibility and tends to zero as the sample size
grows21. Note that Rn is not convex. Other approximations have been proposed, including the
logistic function22 and the convex ramp function23. The probit function approximation tends to be
more accurate and stable than the logistic function approximation21 and is more straightforward to
implement than the ramp function approximation.
3 Methods
We consider a population of M centers where center c has Nc observations, c = 1, ...,M. We
observe data from m centers with nc observations from center c, giving n total observations. We
consider a p-dimensional vector of biomarkers X. Let (X,D) be the biomarkers and outcome
for an arbitrary observation. We use the subscript i on X and D to denote the biomarkers and
outcome, respectively, for the ith observation. We use the superscript c on X and D to denote the
biomarkers and outcome, respectively, for an observation from center c and we use ncD to indicate
the number of cases in center c. We assume the center-specific disease prevalence is non-trivial,
i.e., P(D = 1|C = c) ∈ (0,1), c = 1, ...,M. We consider linear biomarker combinations, θ>X, as
they are often a reasonable choice and have intuitive appeal for clinical collaborators.
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3.1 Direct maximization
We are interested in the aAUC for a linear combination of biomarkers defined by θ , aAUC(θ) =
∑Mc=1 wcAUCc(θ), where wc = P(C = c|D = 1) and AUCc(θ) = P(θ>XcD > θ>XcD¯). As with the
unadjusted AUC, in practice the aAUC is unknown and we instead consider the empirical aAUC.
The empirical aAUC, ˆaAUC = ∑mc=1 wˆc ˆAUCc(θ), is based on empirical estimates of the weights,
wˆc =
ncD
nD
, and the center-specific AUCs, ˆAUCc(θ) = 1ncDncD¯ ∑
ncD
i=1∑
ncD¯
j=1 1(θ
>XcDi > θ
>XcD¯ j). Again,
ˆaAUC is a function of ˆAUCc, which involves indicator functions, making direct maximization
challenging. However, we can use a smooth approximation to ˆAUCc, which in turn provides a
smooth approximation to ˆaAUC. In particular, we propose the SaAUC estimate
θˆ = argmax
θ∈Θ
aRn(θ), (1)
where Θ= {θ ∈ Rp : ||θ ||= 1},
Rcnc(θ) =
1
ncDn
c
D¯
ncD
∑
i=1
ncD¯
∑
j=1
Φ
{
θ>(XcDi−XcD¯ j)/hc
}
≈ ˆAUCc(θ).
In this approximation, hc is a tuning parameter that tends to zero as nc grows. In order to retain
identifiability, constraints must be imposed on θ ; in particular, for any given scalar κ , aRn(θ) =
aRn(κθ). Thus, we constrain ||θ ||= 1 as in23.
The objective function (1) is a sum of smooth functions and is therefore also smooth. Conse-
quently, gradient-based methods (with Lagrange multipliers to incorporate the ||θ ||= 1 constraint)
can be used to obtain θˆ , though this procedure may not yield a global maximum since aRn(θ) is
not convex. Gradient-based methods require starting values θ˜ ; one possibility is to use estimates
from logistic regression. Additionally, in the above formulation, each center has its own tuning pa-
rameter hc. We use hc = σ˜cn
−1/3
c , where σ˜c is the sample standard error of θ˜
>Xc. This mimics the
approach used by others in similar work (e.g.,21) and seems to work well. Since these parameters
are estimated based on the starting value θ˜ , the presence of m tuning parameters does not present
a large computational burden. Bootstrapping could be used to obtain confidence intervals for the
estimated aAUC of the fitted combination θˆ .
3.2 Penalization
In practice, it is unlikely that a given combination will have the same AUC in each center. This
could be due to, for example, differences in the populations of patients at different centers. In
this situation, it may be desirable to construct a biomarker combination that has relatively similar
performance across centers. In particular, it may be worth sacrificing a small amount of the overall
performance (in terms of the aAUC) for less variability in the center-specific AUCs. For instance,
one combination may have an aAUC of 0.7 with center-specific AUCs ranging between 0.55 and
0.85; that is, in some centers the performance is very good, while in others it is quite poor. Another
combination may have an aAUC of 0.68 with center-specific AUCs ranging between 0.64 and 0.72.
This latter combination has slightly worse overall performance, but its discriminatory ability across
centers is much less variable. In the typical multicenter setting, where only a fraction of the centers
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are sampled, this reduced variability may be desirable as it could lead to a fitted combination that
has an AUC in new centers within a narrower range.
To accomplish this, we propose θˆλ = argmaxθ∈Θ
{
aRn(θ)−λ ∑mc=1 wˆc
(
Rcnc(θ)−aRn(θ)
)2}
,
where λ is a fixed penalty parameter, λ ≥ 0. Since
{
aRn(θ)−λ ∑mc=1 wˆc
(
Rcnc(θ)−aRn(θ)
)2} is
the difference of two smooth functions, it can be maximized using gradient-based methods. The
goal of this penalized method is to construct a combination such that its performance in a new
center is similar to what has been observed in previous centers. The notion of “similar” depends
upon the degree of underlying variability across the population of centers as well as the centers
that have been sampled and are used to obtain θˆλ .
3.3 Asymptotic results
In the theorem below, we demonstrate good operating characteristics for the combination θˆλ in
large samples. By setting λ = 0, we obtain asymptotic results for the maximization of aRn(θ)
without penalization. Define Q˜n(θ ;λ ) = aRn(θ)−λ ∑mc=1 wˆc
(
Rcnc(θ)−aRn(θ)
)2 and Q(θ ;λ ) =
aAUC(θ)−λ ∑Mc=1 wc (AUCc(θ)−aAUC(θ))2 . We first present several conditions necessary for
the theorem:
(A1) The m centers are randomly sampled from the population of M centers and nc observations
are randomly sampled from center c, c = 1, ...,m.
(A2) ∑mc=1 |E(wˆc)−wc| → 0 as nc→ ∞, c = 1, ...,m, and m→M such that
√
nc/m→ ∞.
(A3) The centers are independent and within each center, the observations Oci = (D
c
i ,X
c
i ), i =
1, ...,nc, are independent and identically distributed (p+ 1)-dimensional random vectors
such that there exists at least one component of Xc, Xck for some k ∈ {1, ..., p}, with distribu-
tion that has everywhere positive Lebesgue density, conditional on the other Xc components.
(A4) The support of Xc, c = 1, ...,M, is not contained in any proper linear subspace of Rp.
(A5) For fixed λ ≥ 0, both the maximum of Q˜n(θ ;λ ) and the maximum of Q(θ ;λ ) over B= {θ ∈
Rp : ||θ ||= 1, |θk|> 0} are attained.
Theorem 1. Fix λ ≥ 0 and suppose conditions (A1)–(A5) hold. Then
supθ∈B Q(θ ;λ ) = Q(θˆλ ;λ )+op(1) as nc→ ∞, c = 1, ...,m, and m→M such that
√
nc/m→ ∞.
The proof of the theorem is given in Appendix A. We have previously demonstrated that, under
certain conditions, ˆAUCc(θ) converges uniformly in probability to AUCc(θ) and ˆaAUC(θ) con-
verges uniformly in probability to aAUC(θ), and we use these results in the proof of the theorem24.
Briefly, the proof first demonstrates uniform convergence in probability of the difference between
Q(θ ;λ ) and the empirical analogue of Q˜n(θ ;λ ) (that is, with ˆAUCc in place of Rcnc) to zero. The
proof then uses previous results for Rn to demonstrate uniform convergence in probability of the
difference between Q˜n(θ ;λ ) and the empirical analogue of Q˜n(θ ;λ ) to zero. Combining these
results gives the desired conclusion.
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This theorem does not consider the convergence of θˆλ to a particular quantity; instead, the
theorem relates to the operating characteristics of the combination θˆ>λX. By focusing on the per-
formance of the fitted combination, rather than the combination itself, we remove the need to make
additional (restrictive) assumptions. More importantly, since our goal is to develop a combination
with high discriminatory ability, demonstrating good operating characteristics of the fitted combi-
nation is paramount.
3.4 Choosing the penalization parameter λ
In other penalized estimation procedures, such as ridge regression or the lasso, the penalty pa-
rameter λ is typically chosen via cross-validation, where the value of λ that gives the best cross-
validated performance is selected. The motivation for cross-validation is that apparent measures of
performance for a given model (that is, estimates of performance based on the data used to fit the
model) tend to be optimistic25. Cross-validation is one way of addressing this problem.
For our penalized estimation method, we can extend the ideas behind cross-validation to the
multicenter setting. As just described, the goal of cross-validation is typically to get an idea of
the performance in new observations. In the case of data from multiple centers, we would like to
get an idea of the performance in new centers. To that end, we propose the following procedure,
which we call “leave one center out cross-validation” (LOCOCV):
1. Choose a sequence of λ values: {λ1,λ2, ...,λr}
2. For each value of λ and i = 1, ...,m:
(a) Fit the biomarker combination using the data from all but the ith center.
(b) Estimate the AUC of the fitted combination from (a) in the ith center.
3. Plot the m center-specific AUCs from (2b), the corresponding aAUC, and the variability in
the center-specific AUCs around the aAUC in (i) the cross-validation “training” centers and
(ii) the cross-validation “test” centers as a function of λ .
4. Choose an appropriate value of λ , and use this value to fit the biomarker combination using
the data from all m centers.
In some situations, it may be acceptable to sacrifice a small amount of overall performance in
return for a substantial decrease in the variability of the center-specific AUCs. In other situations,
any decline in overall performance may be undesirable. Consequently, we recommend using the
cross-validation plot described above to choose λ , rather than proposing an automated procedure,
as the relative costs and benefits of using a larger or smaller value of λ depend on the specific
context. In other words, individual users must determine the appropriate degree of penalization.
4 Results
4.1 Direct maximization without penalization (λ = 0)
We used simulations to investigate the performance of the proposed direct maximization method.
Most of these simulations were based on the set-up used by23.
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In each simulation, we generated a population of centers and individuals, and obtained training
data by sampling from this population. In particular, we first sampled m centers from the population
of M centers. Then, within each of the m sampled centers, we sampled nc observations from the
Nc observations available in each center (where Nc and nc did not vary across centers). These
observations formed the training data, in which the combinations were constructed. The fitted
combinations were then evaluated in independent test data, which consisted of the Nc observations
in each of the M−m centers not used in the training data. We considered the following settings:
(i) M = 50,Nc = 5,000,m = 6,nc = 200, (ii) M = 500,Nc = 500,m = 50,nc = 50, and (iii) M =
5000,Nc = 200,m = 500,nc = 20.
23 noted that the presence of outliers may lead to diminished performance of logistic regression,
while methods based on maximizing the AUC may be less affected since the AUC is a rank-
based measure. Thus, we considered simulations with and without outliers in the data-generating
model. We focused on the setting of two biomarkers (X = (X1,X2)) and considered (X |C) =
{(1−∆)×Z0}+{∆×Z1} and (D | X,C)∼ Bernoulli
[
f{θC0 +4X1−3X2− (X1−X2)3}
]
, where
Z0 and Z1 were independent bivariate normal random variables with mean zero and respective
covariance matrices
0.2×
(
1 0.9
0.9 1
)
, 2×
(
1 0
0 1
)
,
f (v) = (1+ e−v)−1, θC0 ∼ Uniform(−1,1), and ∆ was an independent Bernoulli random variable
with success probability pi , where pi = 0.05 when outliers were simulated and pi = 0 otherwise.
Other simulations with more complex center effects were considered, including those where the
distribution of the biomarkers and/or the biomarker combination varied by center; the results were
largely similar to those from the scenario described above.
Estimates from robust logistic regression were used as starting values for the proposed SaAUC
method, and the SaAUC method was compared to robust logistic regression and standard uncon-
ditional logistic regression, both with fixed center-specific intercepts. We used the robust logistic
regression method proposed by26. This method uses a deviance function that limits the influence
of individual observations on the model fit, making it more robust to outliers than standard logistic
regression. In addition, when m = 50 or m = 500, we used conditional logistic regression both
to provide starting values for and to compare with the SaAUC method. All methods fit a linear
combination. The simulations were repeated 1000 times.
The results are presented in Table 1. Clearly, when outliers are present, the proposed method
outperforms standard and robust logistic regression, both in terms of the center-adjusted AUC and
the center-specific AUCs. There also appears to be less variability in performance across simu-
lations when the SaAUC approach is used to construct combinations. As was observed by23 for
the AUC, when outliers were not present, the three methods produced combinations with compa-
rable performance. In general, we found the results were very similar when conditional logistic
regression was used to provide starting values for and as a comparison with the SaAUC method
for m = 50 and m = 500 (Table 1 of Appendix B).
The proposed SaAUC method had excellent convergence rates (fewer than 0.03% of simula-
tions failed). Robust logistic regression failed to converge in up to 3% of simulations for m = 50
and up to 15% for m = 500; when this happened, standard unconditional logistic regression was
used to obtain starting values. In addition, when simulating data with outliers, in some instances
the true biomarker combination was so large that it returned a non-value for the outcome D (in R,
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Table 1: Mean (standard deviation) of the aAUC in test data and mean (standard deviation) of the
minimum and maximum center-specific AUCs (AUCc) across the centers in the test data based
on combinations fitted by logistic regression (GLM), robust logistic regression (rGLM), and the
proposed method without penalization (λ = 0; SaAUC). Robust logistic regression estimates were
used as the starting values for the SaAUC method.
Outliers aAUC(θˆGLM) AUCc(θˆGLM) aAUC(θˆ rGLM) AUCc(θˆ rGLM) aAUC(θˆ SaAUC) AUCc(θˆ SaAUC)
Min Max Min Max Min Max
m = 6
Yes 0.6244 0.6065 0.6424 0.6492 0.6315 0.6666 0.6856 0.6684 0.7025
(0.012) (0.013) (0.013) (0.030) (0.031) (0.030) (0.007) (0.008) (0.007)
No 0.7032 0.6866 0.7197 0.7032 0.6866 0.7196 0.7030 0.6864 0.7195
(0.002) (0.004) (0.004) (0.002) (0.004) (0.004) (0.002) (0.004) (0.004)
m = 50
Yes 0.6233 0.5444 0.6992 0.6473 0.5692 0.7215 0.6843 0.6082 0.7564
(0.008) (0.014) (0.012) (0.027) (0.030) (0.026) (0.004) (0.011) (0.009)
No 0.7036 0.6301 0.7731 0.7036 0.6301 0.7731 0.7035 0.6299 0.7730
(0.001) (0.009) (0.008) (0.001) (0.009) (0.008) (0.001) (0.010) (0.008)
m = 500
Yes 0.6221 0.4683 0.7659 0.6333 0.4798 0.7756 0.6796 0.5287 0.8154
(0.004) (0.015) (0.013) (0.013) (0.020) (0.017) (0.004) (0.015) (0.012)
No 0.7038 0.5574 0.8330 0.7038 0.5574 0.8330 0.7037 0.5573 0.8329
(0.001) (0.014) (0.010) (0.001) (0.014) (0.010) (0.001) (0.014) (0.010)
this occurs for (1+ e−v)−1 when v > 800). These observations were removed from the simulated
dataset, though this affected fewer than 0.01% of observations. Finally, for m = 500, some of the
training data centers were concordant (that is, all cases or all controls) and were removed from the
analysis. Up to 11% of simulations had one or two concordant centers in the training data.
Beyond the setting of outliers in the data, we considered a scenario where the true biomarker
combination involved ten biomarkers, but only two were available for fitting. As above, we gen-
erated a population of centers and individuals and obtained training data by sampling from this
population, using the remaining centers as test data in which the fitted combinations were evalu-
ated. In particular, we used M = 50,Nc = 5,000,m = 6, and nc = 200. Here, X = (X1, ...,X10)
and (X|C) ∼ N(µC, I10) where I10 is the 10× 10 identity matrix and µc = −1 for c = 1, ...,10,
µc = 1 for c = 11, ...,40, and µc = 0 for c = 41, ...,50. Center-specific intercepts αC0 were drawn
from a Uniform(0.2,0.8) distribution and (D|X,C) was generated as a Bernoulli random variable
with success probability f (αC0 +X
2
1 − 2X2 +X3− 3X4 +X5− 4X6 +X7−X8 +X9−X10), where
f (v) = (1+e−v)−1. Although the true combination is a function of all ten biomarkers, only X1 and
X2 were available for data analysis. We used estimates from robust logistic regression as starting
values for the proposed SaAUC method, and compared the SaAUC method to robust logistic re-
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gression and standard unconditional logistic regression. All methods fit a linear combination and
the simulations were repeated 1000 times. The mean (standard deviation) aAUC in the test data
for logistic regression, robust logistic regression, and the proposed SaAUC method were 0.6330
(0.018), 0.6284 (0.020), and 0.6453 (0.016), respectively. Thus, the proposed method offers a
small gain in the aAUC over the logistic regression approaches.
4.2 Direct maximization with penalization (λ > 0)
We explored our proposed penalized estimation procedure via simulated datasets. In particular,
we used individual datasets generated under a variety of models to explore how the method may
perform in practice. As was done in the earlier simulations, we first generated a population of
centers and individuals and obtained training data by sampling from this population. Specifically,
we considered a population of M = 50 centers with Nc = 5,000 observations in each and sampled
nc = 200 observations from each of m = 6 centers to form the training data, with the observations
in the remaining M−m = 44 centers serving as test data.
We considered nearly 400 individual datasets; different data-generating mechanisms were used
and included variations on the link function relating (X,C) to P(D = 1|X,C), the distribution of
the biomarkers across centers, and the degree of heterogeneity in the true biomarker combina-
tion across centers. We simulated four independent normally distributed biomarkers with equal
variance and throughout, the true biomarker combination in each center was linear. The details
of the data-generating models for the examples presented here are given in the captions of the
corresponding figures. Estimates from robust logistic regression were used as starting values for
the penalized estimation procedure. For each simulation, we applied the LOCOCV procedure de-
scribed in Section 3.4. We considered 50 values of λ equally-spaced (on the log scale) between 0.1
and 200. This range of values is somewhat arbitrary. In other penalized estimation procedures, it is
common to choose the maximum value of λ to be the value that returns coefficient estimates of 0.
The analogous requirement in the current setting would be the value of λ that gives center-specific
AUCs of 0.5 in all centers. This is only expected to occur when all of the biomarker coefficients
are 0, which cannot happen due to the constraint ||θ || = 1 in the penalized estimation procedure.
The key point is that the range of λ values used here is meant to be illustrative, not prescriptive.
We present a handful of examples here, and include several more in Figures 1–16 of the Ap-
pendix C. All of the plots we present have the same layout: the left plot gives the training data
results, the middle plot gives the results of the LOCOCV procedure, and the right plot gives the
test data results. In each plot, the horizontal axis shows log10λ . Throughout, the solid lines rep-
resent the results of the penalized estimation procedure, the dashed lines represent the standard
logistic regression results, and the dot-dashed lines represent the robust logistic regression results.
In each plot, the left vertical axis displays the AUC, and corresponds to the gray lines (center-
specific AUCs for the penalized estimation procedure) and the black lines (center-adjusted AUCs
for the penalized estimation procedure, robust logistic regression (“rGLM”), and standard logistic
regression (“GLM”)). The right vertical axis shows the variability in the center-specific perfor-
mance on the standard deviation scale and corresponds to the red lines (variability relative to the
adjusted AUC in the training centers) and blue lines (variability relative to the adjusted AUC in the
test centers).
In the test data, the centers are so large that the AUCs calculated in these centers are presumed
to be equal to the population values. In the training data and cross-validation procedure, on the
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other hand, the AUCs are empirical estimates. Thus, in the test data, for a combination θˆ fitted in
the training data, the variability relative to the training centers is ∑M−mc=1 wc(AUCc(θˆ)− ˆaAUC(θˆ))2
and the variability relative to the test centers is ∑M−mc=1 wc(AUCc(θˆ)−aAUC(θˆ))2, where the wc’s
are the weights for the centers in the test data, ˆaAUC is the adjusted AUC for the centers in the
training data, and aAUC and AUCc are the adjusted AUC and the center-specific AUC, respectively,
for the centers in the test data.
Figures 1 and 2 present examples where the LOCOCV procedure does a particularly nice job
of mimicking the patterns in the test data. We encountered some datasets where the penalized
estimation procedure did not work as well. For instance, in a small number of datasets, the vari-
ability increased with increasing λ in the test data, despite the patterns seen in the training data
and the LOCOCV results; Figure 3 presents one such example. In this situation, a value of λ may
be chosen that produces a fitted combination with worse overall performance and more variabil-
ity in center-specific performance than would be obtained without penalization. However, in this
example, the drop in overall performance is not large and the variability is fairly small even when
λ is large. Our simulations indicate that when the centers in the training data are not representa-
tive of the population of centers, the results from the cross-validation procedure may not reflect
the patterns in the test data; such discrepancies would be expected in general when a resampling
procedure is applied to a non-representative sample.
Figure 1: Penalized estimation example 1. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+ e−3v)−1 otherwise. In this example, the penalized estimation procedure produces com-
binations with reduced variability across centers with minimal loss in overall performance (for
modest λ values). Importantly, the LOCOCV results mimic what is seen in the test data.
Problems with convergence were encountered in fewer than 6% of the examples we consid-
ered. Such issues generally arose with the more extreme scenarios we considered and primarily
occurred during cross-validation. In practice, this may require modification of the range of λ
values considered. None of the results presented here had any convergence failures.
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Figure 2: Penalized estimation example 2. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+ e−3v)−1 otherwise. This is an example where the LOCOCV results closely mimic the
patterns seen in the test data, indicating the importance of performing cross-validation.
4.3 TRIBE-AKI study data
To illustrate the methods we have developed, we used data from the TRIBE-AKI study and con-
structed combinations of three biomarkers measured no more than six hours after surgery: urine
neutrophil gelatinase-associated lipocalin (NGAL), plasma heart-type fatty acid binding protein
(h-FABP), and plasma troponin I (TNI). These data are used as illustration and not to report new
findings of the TRIBE-AKI study. As described above, the TRIBE-AKI study involved individuals
at six medical centers who were undergoing cardiac surgery and did not have evidence of AKI
prior to surgery. AKI is a negative side effect of cardiac surgery, often caused by interruptions in
blood flow to the kidneys during the surgery. However, AKI is currently diagnosed by assessing
changes in serum creatinine, which frequently do not occur until several days after surgery. The
aim of the TRIBE-AKI study was to use biomarkers measured soon after surgery to provide an
earlier diagnosis of AKI.
We removed observations with missing values for any of the three biomarkers (leaving 962
observations), log-transformed the biomarker values, and scaled the biomarkers to have equal vari-
ance to improve convergence of the gradient-based algorithm used by our methods. The prevalence
of AKI in each center was between 7.8% and 22.9%, and the sizes of the centers ranged from 53
to 483 patients.
We applied standard logistic regression (“GLM”), robust logistic regression (“rGLM”), and the
proposed SaAUC method to the TRIBE-AKI study data. The fitted combinations (with normalized
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Figure 3: Penalized estimation example 3. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The outcome D was generated as a Bernoulli random variable with success probability
h(αC0 +X1−X2 +X3−X4), where αC0 is a center-specific intercept and f (v) = (1+ e−v)−1. This
is an example where the penalization procedure does not work as well, since the variability in per-
formance across centers increases with increasing λ , despite the patterns seen in the training data
and the LOCOCV.
coefficients) for GLM, rGLM, and SaAUC were
0.0720∗NGAL+0.9917∗h-FABP−0.1068∗TNI
0.0720∗NGAL+0.9917∗h-FABP−0.1068∗TNI
0.0107∗NGAL+0.9585∗h-FABP−0.2849∗TNI,
respectively. The apparent estimated center-adjusted AUCs for these combinations were 0.6878,
0.6878 and 0.6918, respectively. After correcting for resubstitution bias, the center-adjusted AUC
estimates were 0.6819, 0.6820 and 0.6825. Thus, in these data, there was little difference in the
performance of the combinations (though there were clear differences in the fitted combinations
themselves). Furthermore, there was more optimistic bias in the apparent aAUC estimate for the
combination fitted by the SaAUC method, which might be expected in general since the SaAUC
method optimizes a smooth approximation to the estimated aAUC.
Finally, we applied the proposed penalized estimation method to the TRIBE-AKI study data
(Figure 4). The results from the LOCOCV procedure support choosing λ ≈ 101.5, which is ex-
pected to give a reduction in variability in center-specific performance of about 25–30%, with
essentially no loss in overall (center-adjusted) performance. In particular, the LOCOCV results
indicate that when λ = 0.1 (the smallest value considered by LOCOCV), the center-specific AUC
estimates ranged from 0.6042 to 0.7250, but when λ = 101.5, the center-specific AUC estimates
were between 0.6270 and 0.6986. Using λ = 101.5 in the full TRIBE-AKI study dataset yielded
the combination −0.1067∗NGAL+0.9911∗h-FABP+0.0798∗TNI.
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Figure 4: Penalized estimation method applied to the TRIBE-AKI study data. The results from
the LOCOCV procedure support choosing λ ≈ 101.5, which is expected to give a reduction in
variability in center-specific performance of about 25–30%.
5 Discussion
We have proposed a method to construct biomarker combinations by maximizing a smooth ap-
proximation to the center-adjusted AUC. In addition, we have incorporated a penalty term that
can be used to encourage similarity in performance across centers. Our method could be useful
for other discrete nuisance covariates, such as batch, analysis laboratory, or measurement protocol.
We used data on biomarkers measured after cardiac surgery to construct combinations for the diag-
nosis of acute kidney injury, demonstrating the feasibility of our methods. An R package including
code to implement aAUC maximization without penalization, maxadjAUC, is publicly available via
CRAN. In addition, R code to implement maximization with penalization is available on GitHub
(https://github.com/allisonmeisner/maxadjAUCpen).
Multicenter studies include only a subset of centers, so predicted probabilities (risks) for in-
dividuals in new centers cannot be generated without relying on methods that require strong as-
sumptions, e.g., random intercept logistic regression24. The methods proposed here do not provide
predicted probabilities for individuals in either new centers or in the observed centers. Conse-
quently, it is not possible to directly evaluate the calibration of a combination fitted by our method.
Additionally, while we have provided a theoretical result related to the large-sample performance
of combinations fitted by our method, we cannot offer guarantees on the performance of a fitted
combination in a new center. We view this as a fundamental limitation of the data structure, rather
than the methods. Moreover, when biomarkers exhibit “center effects,” further development of
the biomarkers would be required prior to clinical application; after such development, predicted
probabilities would change. A strength of the proposed methodology is that it does not rely on
assumptions about the nature of “center effects” in constructing biomarker combinations; thus, it
allows for the identification of promising combinations for further development while avoiding
such assumptions.
In addition, in multicenter studies, different sampling schemes could be used (e.g., case-control
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or stratified case-control sampling). The estimated weights wˆc would potentially be affected by
different sampling procedures, and may not estimate P(C = c|D = 1). This would in turn affect
the interpretation of the center-adjusted AUC, though it would still be a measure of the conditional
performance. Our methods would then be optimizing this measure of conditional performance.
The sampling scheme could also affect the validity of the asymptotic results we have provided.
Furthermore, if a study involves matching, our methods would need to be modified to adjust the
AUC for the matching in addition to center6.
The adjusted AUC is a reasonable estimand even when the center-specific AUCs of a given
combination are not the same across centers, though it is helpful to consider these center-specific
AUCs, as they provide some insight into how the combination might be expected to perform in a
new center. In addition, differences in performance across centers may be scientifically meaning-
ful and merit further investigation. When assessing center-specific AUCs, it is important to also
consider the sizes of the centers, as estimates of center-specific AUCs from small centers may be
highly variable. One feature of our penalization approach is the use of the weights wˆc in the penalty
function, which reflect the proportion of cases in each center and so will tend to give less weight to
small centers. Furthermore, the optimal combination (in terms of the center-specific AUC) may be
different for each center. Importantly, however, our aim is not to identify the optimal combination
in every center; instead, we are interested in constructing a single combination that performs well
across centers.
Since our smooth approximation function is not convex, further research is needed on the
choice of starting values for the proposed method. It may also be possible to extend the method
proposed by23, which optimizes the convex ramp function approximation to the AUC, to the center-
adjusted AUC. This may lead to further improvements in performance over logistic regression, as
was seen in23 for the unadjusted AUC. In addition, when the centers are very small, the empirical
center-specific AUC will be unreliable. Research is needed into the use of other (possibly paramet-
ric) methods to estimate the center-specific AUC by borrowing information across centers, which
may be necessary when the centers are small. Furthermore, it may be possible to apply the ideas
in this paper to survival data using the method proposed by27 for the covariate-adjusted AUC for
censored data. Extending the proposed method to other center-adjusted measures of performance,
such as the partial AUC or the true positive rate for a fixed false positive rate, is another avenue for
future research.
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Appendix A
Proof. Proof of Theorem 1. First we will show supθ∈B
∣∣Q˜n(θ ;λ )−Q(θ ;λ )∣∣= op(1). Let
Qn(θ ;λ ) = ˆaAUC(θ)−λ
m
∑
c=1
wˆc
( ˆAUCc(θ)− ˆaAUC(θ))2 .
We can write
sup
θ∈B
∣∣Q˜n(θ ;λ )−Q(θ ;λ )∣∣≤ sup
θ∈B
∣∣Q˜n(θ ;λ )−Qn(θ ;λ )∣∣+ sup
θ∈B
|Qn(θ ;λ )−Q(θ ;λ )| .
Under conditions (A1)–(A4), we have shown (Lemma 1 and Theorem 1 in Meisner et al.24) that
supθ∈B
∣∣ ˆaAUC(θ)−aAUC(θ)∣∣= op(1) and
supθ∈B
∣∣ ˆAUCc(θ)−AUCc(θ)∣∣= op(1), c = 1, ...,M. We can write
sup
θ∈B
|Qn(θ ;λ )−Q(θ ;λ )|
≤ sup
θ∈B
∣∣ ˆaAUC(θ)−aAUC(θ)∣∣
+λ sup
θ∈B
∣∣∣∣∣ M∑c=1 wc(AUCc(θ)−aAUC(θ))2−
m
∑
c=1
wˆc( ˆAUCc(θ)− ˆaAUC(θ))2
∣∣∣∣∣
≤ sup
θ∈B
∣∣ ˆaAUC(θ)−aAUC(θ)∣∣
+λ
M
∑
c=m+1
sup
θ∈B
∣∣wc(AUCc(θ)−aAUC(θ))2∣∣
+λ sup
θ∈B
∣∣∣∣∣ m∑c=1{wc(AUCc(θ)−aAUC(θ))2− wˆc( ˆAUCc(θ)− ˆaAUC(θ))2}
∣∣∣∣∣ ,
where ∑Mc=m+1 supθ∈B
∣∣wc(AUCc(θ)−aAUC(θ))2∣∣ = o(1) as m → M. Then by Theorem 1 in
Meisner et al.24,
sup
θ∈B
|Qn(θ ;λ )−Q(θ ;λ )| ≤ op(1)+o(1)+λ
m
∑
c=1
sup
θ∈B
∣∣wcY c1 (θ)2− wˆc(Y c2 (θ)+Y c1 (θ)+Y3(θ))2∣∣ ,
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where Y c1 (θ) = AUCc(θ)− aAUC(θ), Y c2 (θ) = ˆAUCc(θ)−AUCc(θ), and Y3(θ) = aAUC(θ)−
ˆaAUC(θ); note that |Y c1 (θ)| ≤ 1, |Y c2 (θ)| ≤ 1 and |Y3(θ)| ≤ 1. Then
sup
θ∈B
|Qn(θ ;λ )−Q(θ ;λ )|
≤op(1)+o(1)+λ
m
∑
c=1
sup
θ∈B
∣∣(wc− wˆc)Y c1 (θ)2
−wˆc
{
Y c2 (θ)
2+Y3(θ)2+2Y c1 (θ)Y
c
2 (θ)+2Y
c
1 (θ)Y3(θ)+2Y
c
2 (θ)Y3(θ)
}∣∣
≤op(1)+o(1)+λ
m
∑
c=1
sup
θ∈B
∣∣(wc− wˆc)Y c1 (θ)2∣∣+λ m∑
c=1
sup
θ∈B
∣∣−wˆcY c2 (θ)2∣∣
+λ
m
∑
c=1
sup
θ∈B
∣∣−wˆcY3(θ)2∣∣+λ m∑
c=1
sup
θ∈B
|−2wˆcY c1 (θ)Y c2 (θ)|
+λ
m
∑
c=1
sup
θ∈B
|−2wˆcY c1 (θ)Y3(θ)|+λ
m
∑
c=1
sup
θ∈B
|−2wˆcY c2 (θ)Y3(θ)| .
We have (by Lemma 1 and Theorem 1 in Meisner et al.24) supθ∈B
∣∣Y c2 (θ)∣∣ = op(1),c = 1, ...,M
and supθ∈B |Y3(θ)|= op(1). This gives
sup
θ∈B
∣∣∣(wc− wˆc) [Y c1 (θ)]2∣∣∣= |wc− wˆc| sup
θ∈B
[Y c1 (θ)]
2 ≤ |wc− wˆc|
sup
θ∈B
∣∣∣−wˆc [Y c2 (θ)]2∣∣∣= wˆc sup
θ∈B
[Y c2 (θ)]
2 ≤ wˆc sup
θ∈B
|Y c2 (θ)|= wˆcop(1)
sup
θ∈B
∣∣∣−wˆc [Y3(θ)]2∣∣∣= wˆc sup
θ∈B
[Y3(θ)]2 ≤ wˆc sup
θ∈B
|Y3(θ)|= wˆcop(1)
sup
θ∈B
|−2wˆcY c1 (θ)Y c2 (θ)|= wˆcop(1)
sup
θ∈B
|−2wˆcY c1 (θ)Y3(θ)|= wˆcop(1)
sup
θ∈B
|−2wˆcY c2 (θ)Y3(θ)|= wˆcop(1).
Since ∑mc=1 wˆc = 1 for every m,
sup
θ∈B
|Qn(θ ;λ )−Q(θ ;λ )| ≤ op(1)+o(1)+λ
m
∑
c=1
|wc− wˆc| .
Furthermore, we have previously shown (Theorem 1 in Meisner et al.24) that
∑mc=1 |wc− wˆc|= op(1) as nc→∞, c= 1, ...,m, and m→M such that
√
nc/m→∞. Thus, supθ∈B |Qn(θ ;λ )−Q(θ ;λ )|=
op(1).
Now consider supθ∈B
∣∣Q˜n(θ ;λ )−Qn(θ ;λ )∣∣. We will first show supθ∈B ∣∣aRn(θ)− ˆaAUC(θ)∣∣
= op(1). Ma and Huang22 demonstrated that supθ∈B
∣∣Rcnc(θ)− ˆAUCc(θ)∣∣= op(1) as nc→ ∞. We
can write
sup
θ∈B
∣∣aRn(θ)− ˆaAUC(θ)∣∣≤ m∑
c=1
wˆc sup
θ∈B
∣∣Rcnc(θ)− ˆAUCc(θ)∣∣≤ m∑
c=1
wˆcop(1) = op(1)
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since ∑mc=1 wˆc = 1 for every m.
Now consider supθ∈B
∣∣Q˜n(θ ;λ )−Qn(θ ;λ )∣∣. We can write
sup
θ∈B
∣∣Q˜n(θ ;λ )−Qn(θ ;λ )∣∣
≤ sup
θ∈B
∣∣aRn(θ)− ˆaAUC(θ)∣∣
+λ sup
θ∈B
∣∣∣∣∣ m∑c=1{wˆc( ˆAUCc(θ)− ˆaAUC(θ))2− wˆc(Rcnc(θ)−aRn(θ))2}
∣∣∣∣∣
≤op(1)+λ
m
∑
c=1
sup
θ∈B
∣∣wˆcZc1(θ)2− wˆc(Zc2(θ)+Zc1(θ)+Z3(θ))2∣∣ ,
where Zc1(θ)= ˆAUCc(θ)− ˆaAUC(θ), Zc2(θ)=Rcnc(θ)− ˆAUCc(θ), and Z3(θ)= ˆaAUC(θ)−aRn(θ);
note that |Zc1(θ)| ≤ 1, |Zc2(θ)| ≤ 1 and |Z3(θ)| ≤ 1. This gives
sup
θ∈B
∣∣Q˜n(θ ;λ )−Qn(θ ;λ )∣∣≤op(1)+λ m∑
c=1
sup
θ∈B
∣∣−wˆcZc2(θ)2∣∣
+λ
m
∑
c=1
sup
θ∈B
∣∣−wˆcZ3(θ)2∣∣+λ m∑
c=1
sup
θ∈B
|−2wˆcZc1(θ)Zc2(θ)|
+λ
m
∑
c=1
sup
θ∈B
|−2wˆcZc1(θ)Z3(θ)|+λ
m
∑
c=1
sup
θ∈B
|−2wˆcZc2(θ)Z3(θ)| .
We have that supθ∈B
∣∣Zc2(θ)∣∣= op(1),c = 1, ...,M and supθ∈B |Z3(θ)|= op(1). This gives
sup
θ∈B
∣∣∣−wˆc [Zc2(θ)]2∣∣∣= wˆc sup
θ∈B
[Zc2(θ)]
2 ≤ wˆcop(1)
sup
θ∈B
∣∣∣−wˆc [Z3(θ)]2∣∣∣= wˆc sup
θ∈B
[Z3(θ)]2 ≤ wˆcop(1)
sup
θ∈B
|−2wˆcZc1(θ)Zc2(θ)|= wˆcop(1)
sup
θ∈B
|−2wˆcZc1(θ)Z3(θ)|= wˆcop(1)
sup
θ∈B
|−2wˆcZc2(θ)Z3(θ)|= wˆcop(1).
Since ∑mc=1 wˆc = 1 for every m, we have supθ∈B
∣∣Q˜n(θ ;λ )−Qn(θ ;λ )∣∣= op(1).
Combining these results, we have supθ∈B
∣∣Q˜n(θ ;λ )−Q(θ ;λ )∣∣= op(1). Then∣∣∣∣Q(θˆλ ;λ )− sup
θ∈B
Q(θ ;λ )
∣∣∣∣≤ ∣∣∣∣sup
θ∈B
Q(θ ;λ )− sup
θ∈B
Q˜n(θ ;λ )
∣∣∣∣+ ∣∣∣∣sup
θ∈B
Q˜n(θ ;λ )−Q(θˆλ ;λ )
∣∣∣∣
≤ sup
θ∈B
∣∣Q(θ ;λ )− Q˜n(θ ;λ )∣∣+ ∣∣Q˜n(θˆλ ;λ )−Q(θˆλ ;λ )∣∣
≤op(1)+ sup
θ∈B
∣∣Q˜n(θ ;λ )−Q(θ ;λ )∣∣= op(1),
giving supθ∈B Q(θ ;λ ) =Q(θˆλ ;λ )+op(1) as nc→∞, c= 1, ...,m, and m→M such that
√
nc/m→
∞.
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Appendix B
Table 1: Mean (standard deviation) of the aAUC in test data and mean (standard deviation) of
the minimum and maximum center-specific AUCs (AUCc) across the centers in the test data based
on combinations fitted by conditional logistic regression (GLM) and the proposed method without
penalization (λ = 0; SaAUC). Conditional logistic regression estimates were used as the starting
values for the SaAUC method.
Outliers aAUC(θˆGLM) AUCc(θˆGLM) aAUC(θˆ SaAUC) AUCc(θˆ SaAUC)
Min Max Min Max
m = 50
Yes 0.6233 0.5444 0.6992 0.6824 0.6062 0.7547
(0.008) (0.014) (0.012) (0.004) (0.011) (0.009)
No 0.7036 0.6301 0.7731 0.7035 0.6299 0.7730
(0.001) (0.009) (0.008) (0.001) (0.010) (0.008)
m = 500
Yes 0.6221 0.4684 0.7659 0.6764 0.5253 0.8128
(0.004) (0.015) (0.013) (0.003) (0.015) (0.012)
No 0.7038 0.5574 0.8330 0.7037 0.5573 0.8329
(0.001) (0.014) (0.010) (0.001) (0.014) (0.010)
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Appendix C
Figure 1: Penalized estimation example 4. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability f (αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and f (v) = (1+e−v)−1. This is an
example where the LOCOCV procedure does very well in mimicking the patterns seen in the test
data.
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Figure 2: Penalized estimation example 5. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability f (αC0 + γ1CX1−
γ2CX2 + γ3CX3− γ4CX4), where αC0 is a center-specific intercept and f (v) = (1+ e−v)−1. This il-
lustrates a setting where there is a clear benefit to penalizing as there is a reduction in variability
with little loss in overall performance.
Figure 3: Penalized estimation example 6. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+ e−3v)−1 otherwise. This is an example where the LOCOCV results are inconclusive in
terms of which value of λ should be chosen.
22
Figure 4: Penalized estimation example 7. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+e−3v)−1 otherwise. This is an example where the penalization procedure does not work as
well, since in the test data, the aAUC decreased more quickly with increasing λ than was indicated
by the LOCOCV procedure and the training data.
Figure 5: Penalized estimation example 8. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+ e−3v)−1 otherwise. In this example, the LOCOCV procedure does a nice job capturing
the trends seen in the test data.
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Figure 6: Penalized estimation example 9. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+ e−3v)−1 otherwise. In this example, there is a clear benefit to penalization.
Figure 7: Penalized estimation example 10. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+ e−3v)−1 otherwise. In this example, there is a clear benefit to penalization for a range of
λ values.
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Figure 8: Penalized estimation example 11. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+ e−3v)−1 otherwise. In this example, there is a clear benefit to penalization.
Figure 9: Penalized estimation example 12. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability f (αC0 + γ1CX1−
γ2CX2 + γ3CX3− γ4CX4), where αC0 is a center-specific intercept and f (v) = (1+ e−v)−1. Here,
there is a clear benefit to penalization, and the overall performance even increases slightly as λ
increases.
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Figure 10: Penalized estimation example 13. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability f (αC0 + γ1CX1−
γ2CX2 + γ3CX3− γ4CX4), where αC0 is a center-specific intercept and f (v) = (1+ e−v)−1. In this
example, there is a definite benefit to penalization for a range of λ values.
Figure 11: Penalized estimation example 14. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+e−3v)−1 otherwise. In this example, the LOCOCV procedure returns somewhat inconclu-
sive results, making the choice of λ less clear.
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Figure 12: Penalized estimation example 15. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The outcome D was generated as a Bernoulli random variable with success probability
g(αC0 +X1−X2 +X3−X4), where αC0 is a center-specific intercept and g(v) = (1+ e−v/3)−1 for
v < 0 and (1+ e−3v)−1 otherwise. In this example, the LOCOCV procedure is a bit misleading,
when compared to the results in the test data.
Figure 13: Penalized estimation example 16. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability f (αC0 + γ1CX1−
γ2CX2 + γ3CX3− γ4CX4), where αC0 is a center-specific intercept and f (v) = (1+ e−v)−1. In this
example, the LOCOCV procedure is a bit misleading, when compared to the results in test data.
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Figure 14: Penalized estimation example 17. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability g(αC0 + γ1CX1−
γ2CX2+ γ3CX3− γ4CX4), where αC0 is a center-specific intercept and g(v) = (1+e−v/3)−1 for v < 0
and (1+ e−3v)−1 otherwise. In this example, the variability in performance in test data increases
slightly with increasing λ , though this is not reflected in the LOCOCV results.
Figure 15: Penalized estimation example 18. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2iC), i=
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability f (αC0 + γ1CX1−
γ2CX2 + γ3CX3− γ4CX4), where αC0 is a center-specific intercept and f (v) = (1+ e−v)−1. In this
example, the overall performance in test data decreases more rapidly with increasing λ than is
suggested by the LOCOCV results.
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Figure 16: Penalized estimation example 19. The four biomarkers (X1,X2,X3,X4) were indepen-
dently normally distributed with mean 0 and center-specific variances, i.e., (Xi|C)∼ N(0,σ2C), i =
1,2,3,4. The relationships between the biomarkers and P(D = 1) were allowed to vary by center
and these variations (defined by (γ1C,γ2C,γ3C,γ4C)) differed across the four biomarkers. The out-
come D was generated as a Bernoulli random variable with success probability f (αC0 + γ1CX1−
γ2CX2 + γ3CX3− γ4CX4), where αC0 is a center-specific intercept and f (v) = (1+ e−v)−1. In this
example, the relationship between λ and variability in performance in the test data is somewhat
unusual and is not seen in the LOCOCV results.
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